Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Oct 14, 2024. (Total: 232476Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 30 (of 187 Records)

Next

Query Trace: Lung Neoplasms and meta-analysis and EGFR[original query]
Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification.
Technology in cancer research & treatment 2022 9 21 15330338221128414.
Sun Dantong, Tao Junyan, Yan Weihua, Zhu Jingjuan, Zhou Hai, Sheng Yingying, Xue Chaofan, Li Hong, Hou Hel
RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis.
Frontiers in oncology 2022 12 12 1024833.
Wu Min, Jiang Jun, Zhang Xuewen, Chen Jie, Chang Qiaomei, Chen Ro
A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer.
Medicine 2022 12 101 (47): e31894.
Cui Ran, Wei Chun, Li Xianyi, Jiang
EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review.
Medicina (Kaunas, Lithuania) 2022 11 58 (11): .
Chen Chang-Hung, Chou Deng-Wei, Chung Kuo-Mou, Chang Han-
Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis.
Oncology letters 2022 Nov 24 (5): 384.
Lan Bo, Zhao Na, Du Kang, Leng Baola
Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.
Acta oncologica (Stockholm, Sweden) 2022 10 61 (11): 1347-1353.
Li Li, Huang Qin, Sun Jianhai, Yan Fei, Wei Wujie, Li Zihui, Liu Li, Deng J
First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
Therapeutic advances in chronic disease 2022 10 13 20406223221125706.
Chen Chongxiang, Zhang Chunning, Lin Huaming, Liu Qianyin, Wu Limian, Zhou Chengzhi, Zhang Jiex
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Thoracic cancer 2023 9 .
Huang-Chih Chang, Chin-Chou Wang, Chia-Cheng Tseng, Kuo-Tung Huang, Yu-Mu Chen, Yu-Ping Chang, Chien-Hao Lai, Wen-Feng Fang, Meng-Chih Lin, Hung-Yi Chua
Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
Thoracic cancer 2023 9 .
Huang-Chih Chang, Kuo-Tung Huang, Chia-Cheng Tseng, Yu-Mu Chen, Chien-Hao Lai, Yu-Ping Chang, Yung-Che Chen, Hung-Yi Chuang, Chin-Chou Wa
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.
European journal of medical research 2023 8 28 (1): 302.
Ruijian Li, Weiyi Li, Fang Zhang, Shanshan
The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.
Cancer medicine 2023 8 .
Zhen Wang, Fang Zhou, Shan Xu, Kang Wang, Huan Di
Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis.
BMC pulmonary medicine 2023 6 23 (1): 207.
Di Hu, Yan-Yan Zhou, Hong-Bo Ma, Miao-Miao Tao, Qun-Zhen Huang, Zhen-Zhou Yang, Qi Zh
Infection with human cytomegalovirus, Epstein-Barr virus, and high-risk types 16 and 18 of human papillomavirus in EGFR-mutated lung adenocarcinoma.
Croatian medical journal 2023 5 64 (2): 84-92.
Suzana Harabajsa, Hajdi Šef?i?, Marija Klasi?, Marija Milavi?, Snježana Židovec Lepej, Ivana Grgi?, Matea Zajc Petranovi?, Marko Jakopovi?, Silvana Smojver-Ježek, Petra Kor
Should We Perform Repeated Re-Biopsy for the Detection of T790M Mutation?
Cancer research and treatment 2023 4 .
Saerom Kim, Soo Han Kim, Jinmi Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop E
Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
World journal of surgical oncology 2023 2 21 (1): 45.
Zhao Ning, Wu Zhuo-Peng, Yang Jie, Feng Wei-Neng, Yang Sheng-Li, Luo Ying, Ye Jun, Wang Fei, Zhang Xiao-Wen, Xiao Ye, Wu Ling-Ling, Gu Wei-Qu
Distinguishing EGFR mutant subtypes in stage IA non-small cell lung cancer using the presence status of ground glass opacity and final histologic classification: a systematic review and meta-analysis.
Frontiers in medicine 2023 12 10 1268846.
Jianhao Qiu, Zheng Ma, Rongyang Li, Chenghao Qu, Kun Wang, Binyan Liu, Yu Tian, Hui Ti
Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis.
Clinical Medicine Insights. Oncology 2023 12 17 11795549231215968.
Zexun Mo, Meifeng Ye, Hua He, Xiaomei Huang, Weihong Guo, Ziwen Zhao, Yujun Li, Shuquan W
Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis.
Clinical lung cancer 2023 11 .
Fumihiro Kashizaki, Hao Chen, Atsushi Miyasaka, Nanami Tsuchiya, Chihiro Yamada, Shunsuke Okazaki, Mai Kaneko, Taiki Kano, Yohei Kameda, Akitomo Kikuchi, Kentaro Yumoto, Hiroyuki Osawa, Harumi Koizumi, Kenichi Takahashi, Takeshi Kane
Correlation between carcinoembryonic antigen (CEA) expression and EGFR mutations in non-small-cell lung cancer: a meta-analysis.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2023 11 .
Tian Gan, Wenting An, Yun Long, Jingting Wang, Hanfei Zhang, Meiyan Li
Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy.
Journal for immunotherapy of cancer 2023 10 11 (10): .
Zichun Li, Xuanye Zhang, Yuhong Wang, Zhixin Yu, Chunlong Yang, Yixin Zhou, Shaodong Ho
Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Thoracic cancer 2023 1 14 (6): 535-543.
Dai Jiali, Liu Xinyin, Li Jun, Qu Tianyu, Cui Yanan, Jin Shidai, Zhang Erbao, Guo Renh
Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non?small?cell lung cancer: A meta analysis.
Clinics (Sao Paulo, Brazil) 2023 1 78 100152.
Yi Min, He Ting, Wang Kaijin, Wei Yongga
Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis.
Oncology letters 2023 1 25 (2): 62.
Obradovic Jasmina, Todosijevic Jovana, Jurisic Vladim
Immunotherapy plus chemotherapy for patients with EGFR-mutated non-squamous cell lung cancer for disease progression after EGFR tyrosine-kinase inhibitor: A meta-analysis of randomized controlled trials.
Oncology 2024 9 1-26.
Ahmed A Refae, Rafat I Abu Shakra, Ezzeldin M Ibrah
Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment.
American journal of clinical oncology 2024 9 .
Zaheer Qureshi, Faryal Altaf, Abdur Jamil, Rimsha Siddiq
Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis.
ESMO open 2024 8 9 (9): 103660.
Z Piotrowska, B Y Yeap, J F Gain
A meta-analysis of liquid biopsy versus tumor histology for detecting EGFR mutations in non-small cell lung cancer.
Translational oncology 2024 7 47 102022.
Jing Cai, Wanning Wang, Wenlong Zha
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials.
Expert review of anticancer therapy 2024 5 1-6.
Thierry Landre, Jean-Baptiste Assié, Kader Chouahnia, Gaetan Des Guetz, Jean-Bernard Auliac, Christos Choua
The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis.
The clinical respiratory journal 2024 4 18 (4): e13748.
Liuxian Guo, Guojin Zhou, Min Huang, Kejing Tang, Jing Xu, Jie Ch
Efficacy of Adjuvant First-Generation TKIs versus Chemotherapy in Patients with Completely Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis.
Cancer investigation 2024 1 1-12.
Bin Shen, Dongping Wu, Jianjiang Liu, Yang Ya
TOP